day 1 agenda
6th Edition of Innovations and State of the Art in ALZHEIMER'S & DEMENTIA at Oct 01 - 02, 2025 at Berlin, Germany (Hybrid Event) |
|
Day -1(October 01, 2025) | |
Tentative Program | |
09:00-09:30 | KeynoteTalk: Genistein (4′,5,7-trihydroxyisoflavone) corrects behavior and improves biochemical parameters in animal models of Alzheimer's disease through autophagy stimulation |
Grzegorz Wegrzyn, University of Gdansk, Poland | |
09:30-10:00 | Slot Available |
10:00-10:30 | KeynoteTalk: Neurogenesis And Plasticity Processes Are Similarly Affected And Damaged In Alzheimer´s Disease |
José Julio Rodríguez Arellano, IKERBASQUE, Spain | |
Group Photo & Refreshment Break (10:30-10:50) | |
Technical session-I | |
Themes: Alzheimer’s Research and Therapy, Advances in Alzheimer’s and Dementia Research |
|
10:50-11:10 | Changes in expression of VGF, SPECC1L, HLA-DRA, and RANBP3L act with APOE E4 to alter risk for late-onset Alzheimer’s disease |
Amanda J. Myers, University of Miami, USA | |
11:10-11:30 | Slot Available |
11:30-11:50 | In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimer's disease |
Paul Chazot, Durham University, UK | |
11:50-12:10 | Biological prognosis toolbox for Alzheimer’s disease and other cognitive neurodegenerative diseases |
Marc Teichmann, PITIE SALPETRIERE, France | |
12:10-12:30 | Structural Changes in Cerebral Microvasculature Induced by Ferroptosis Contribute to Blood–Brain Barrier Destruction in Alzheimer's Disease: An Autopsy Study |
Yuan Cao, Peking Union Medical College Hospital, China | |
12:30-12:50 | Three scenarios for amyloid transformation |
Irena K. Roterman, Jagiellonian University – Medical College , Poland | |
12:50-13:10 | Advancing dementia screening, care, and research in Kenya: challenges and opportunities |
DAVID NDETEI, University of Nairobi / Africa Institute of Mental and Brain Health, Kenya | |
Lunch Break @ Restaurant (13:10-14:00) | |
Technical session-II | |
Themes: Dementia care research and Practice, Dementia diagnosis, treatment & Amyloid and Tau Protein |
|
14:00-14:20 | Cerebral Capillopathy Nexus of Neurodegenerative disease |
Charles R Joseph, Liberty University College of Osteopathic Medicine, USA | |
14:20-14:40 | Older adults with dementia:knowledge and attitudes of physicians in health units |
ANA BEATRIZ QUINTES STEINER, UNIFESP, Brazil | |
14:40-15:00 | Slot Available |
15:00-15:20 | Short and Long-term Effects of Transcranial Alternating Electrical Stimulation Paired with Cognitive Exercises as a Treatment for Cognitive Impairment |
Zahra Moussavi, University of Manitoba, Canada | |
15:20-15:40 | Dihydromyricetin as a Dual-Target Neuroprotector: Clearing Tau and Aβ for Alzheimer's Disease Intervention |
Judy Qiao, Towncom International Group, USA | |
15:40:16:00 | Extracellular Tau and S100A9 proteins induce phagoptosis of live neurons |
Vilma Borutaite, Lithuanian University of Health Sciences, Lithunia | |
16:20:16:40 | Slot Available |
Refreshment Break(16:40-17:00) | |
Note: This is a Tentative program, subjects and timings will changes. | |
Abstract submissions are open now. To schedule your talk in the program please email to: [email protected] | |
Day-1 Concludes |
day 2 agenda
Day -2(October 02, 2025) | |
Tentative Program | |
09:00-09:30 | Keynote Talk: Exploring Immune Dysregulation and Gut-Nutrient Disruption in Alzheimer’s Disease Pathology |
Catherine C L Wong, Peking Union Medical College Hospital, China | |
09:30-10:00 | Slot Available |
10:00-10:30 | Slot Available |
Group Photo & Refreshment Break (10:30-10:50) | |
Technical session-III | |
Themes: Neurodegenerative Diseases,Risk reduction and prevention & Clinical Trials and Therapeutics |
|
10:50-11:10 | Heparan sulfate modified protein signaling and neurodegenerative disease |
Scott Selleck, Pennsylvania State University, USA | |
11:10-11:30 | Maternal and early life exposure induced AD- like pathophysiology |
Aluru Parithathvi, Manipal School of Life Sciences, India | |
11:30-11:50 | Semaglutide ameliorates Alzheimer’s disease and restores oxytocin in APP/ PS1 mice and human brain organoid models |
Zhihui Zhong, Sichuan University West China Hospital, China | |
11:50-12:10 | Hearing Loss &Tinnitus – Reducing the Risk of Cognitive Decline |
Keith N. Darrow, Worcester State University, USA | |
12:10-12:30 | Slot Available |
12:30-12:50 | One-week inpatient cognitive behavioral therapy for insomnia: a retrospective study |
Qifang Li, Tongji university, China | |
12:50-13:10 | A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease |
Alison Buchholz, The Johns Hopkins University School of Medicine, USA | |
13:10-13:30 | The efficacy of Sham rTMS stimulation |
Brian Lithgow, University of Manitoba, Canada | |
Lunch Break @ Restaurant (13:30-14:30) | |
Poster Presentations | |
PP-1 | In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease |
Yunxi Zhang, Durham University, UK | |
PP-2 | Probing Monoclonal Antibody Specificity for Designing Alzheimer's Vaccines |
Anne-Cathrine Vogt, University of Bern, Switzerland | |
PP-3 | Slot Available |
PP-4 | Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer’s Disease and ALS Risk: The UK Rugby Health Study |
Norah Alanazi, Durham University, UK | |
PP-5 | FUS-mediated Blood-brain barrier disruption for delivering anti-A? antibodies in 5XFAD Alzheimer’s disease mice |
Christakis Damianou, Cyprus University of Technology, Cyprus | |
PP-6 | Slot Available |
Abstract submissions are open now. To schedule your talk in the program please email to: [email protected] | |
Day-2 Concludes |
posters agenda
Poster Presentations | |
PP-1 | In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease |
Yunxi Zhang, Durham University, UK | |
PP-2 | FUS-mediated Blood-brain barrier disruption for delivering anti-A? antibodies in 5XFAD Alzheimer’s disease mice |
Christakis Damianou, Cyprus University of Technology, Cyprus | |
PP-3 | Slot Available |
PP-4 | Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer’s Disease and ALS Risk: The UK Rugby Health Study |
Norah Alanazi, Durham University, UK | |
PP-5 | Probing Monoclonal Antibody Specificity for Designing Alzheimer's Vaccines |
Anne-Cathrine Vogt, University of Bern, Switzerland | |
PP-6 | Slot Available |
Abstract submissions are open now. To schedule your talk in the program please email to: [email protected] |
posters agenda
6th Edition of Innovations and State of the Art in ALZHEIMER'S & DEMENTIA at Oct 01 - 02, 2025 at Berlin, Germany (Hybrid Event) |
|
Tentative Program | |
Day -1(October 01, 2025) | |
Virtual Program | |
09:00-09:20 | CareWindow: Enhancing Communication for Seniors and Individuals with Disabilities |
Zachary Bailey, Care Window, Australia | |
09:20-09:40 | Slot Available |
09:40-10:10 | Keynote Talk: Sex-specific brain protection in the clinical scenario: the case of davuentide |
Illana Gozes, Tel Aviv University, Israel | |
10:10-10:30 | Understanding Depression Through Metaphors: Insights into Cognitive and Behavioral Patterns in Online Health Communities |
Jiayi Shi, Xi'an Jiaotong University, China | |
10:30-10:50 | Slot Available |
10:50-11:10 | From Phenotype Drug Screening to Biological Target identification for Alzheimer’s disease-modifying development |
SERGEANT Nicolas, University of Lille, France | |
11:10-11:30 | Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial |
Dean Ornish, Preventive Medicine Research Institute, USA | |
11:30-11:50 | Slot Available |
11:50-12:10 | Successes and Challenges: Insights from the first six months of the CONNECT program |
Chitrali R. Mamlekar & Melissa A. Alunni, Misericordia University, USA | |
12:10-12:30 | Slot Available |
12:30-12:50 | Clinicians' Reluctance to Implement a Deeply Demented Patient's Advance Directive: A Broken Moral Compass |
Norman L. Cantor, Retired from Rutgers University, USA | |
12:50-13:10 | Slot Available |
13:10-13:30 | P re existing cognitive disorders and Long COVID neurocognitive sequelae : Why Do We Know So Little? |
Caroline Jose, Vitalité Health Network, Canada | |
13:30-13:50 | Slot Available |
13:50-14:10 | An integrative review about electrophysiological biomarkers of cognitive impairment in Alzheimer’s disease: A developing relationship |
Ezra C. Holston, University of Nevada Reno, USA | |
14:10-14:30 | Revised Criteria for Diagnosis and Staging of Alzheimer's Disease |
Clifford R. Jack, Mayo Clinic, USA | |
14:30-14:50 | Slot Available |
14:50-15:10 | Aging as a target for the prevention and treatment of Alzheimer’s disease |
Raymond Scott Turner, Georgetown University, USA | |
15:10-15:30 | Futuristic Alzheimer's therapy: acoustic-stimulated piezoelectric nanospheres for amyloid reduction |
Manju Sharma, University of Georgia, USA | |
15:30-15:50 | Slot Available |
Day-1 Concludes | |
Day -2(October 02, 2025) | |
Virtual Program | |
09:00-09:20 | A perspective on physical therapy approaches in motor function neurorehabilitation |
Fengxue Qi, Beijing Sport University, China | |
09:20-09:40 | Slot Available |
09:40-10:00 | Students’ core self-evaluation, psychological capital, and academic engagement: A case study of Romania and Serbia |
Elena Mirela Samfira, University of Life Sciences „King Mihai I” from Timisoara, Romania | |
10:00-10:20 | The crosstalk between CREB and PER2 mediates the transition between mania- and depression-like behavior |
Xinling Wang, Freiburg University Medical Center, Germany | |
10:20-10:40 | Exploring the Developmental Regulation Network of Human Serotonin Neurons via Florescent Reporter Systems |
Jianfeng LU, Tongji University, China | |
10:40-11:00 | Slot Available |
11:00-11:20 | OXYGEN-OZONE THERAPY AND COGNITIVE FRAILTY: A NONPHARMACOLOGICAL APPROACH TO POTENTIALLY RESOLVE IMMUNE AND INFLAMMATORY DYSFUNCTIONS |
Antonio Carlo Galoforo, University of Pavia, Italy | |
11:20-11:40 | Slot Available |
11:40-12:00 | Understanding Systems and Cognitive Process to Lead Change with Compassion |
Elizabeth Wilhelm-Alderton & Renae Swanson, University of Wisconsin - Oshkosh, USA | |
12:00-12:20 | Proposed Micronutrient Mixture, Probiotics, Collagen Peptides, Omega3, and Cannabidiol (CBD) may Reduce Aging, and Development and Progression of Alzheimer’s disease, and Improve its Treatment |
Kedar N Prasad, Engage Global, Inc, USA | |
12:20-12:40 | Severe COVID-19 is associated with transcriptomic signatures of aging in the human brain |
Maria Mavrikaki, Harvard Medical School, USA | |
12:40-13:00 | Slot Available |
13:00-13:20 | Psychosocial factors associated with the risk of developing psychosis in Mexico |
Tecelli Domínguez Martínez, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico | |
13:20-13:40 | Amyloid β fragments that suppress oligomers but not fibrils are cytoprotective |
Suren A. Tatulian, University of Central Florida, USA | |
13:40-14:00 | Passive exposure to novel stimuli drives neural adaptation that encodes stimulus statistics in songbird auditory forebrain |
David S. Vicario, Rutgers University, USA | |
14:00-14:20 | Slot Available |
14:20-14:40 | Blood-brain barrier permeability contributes to cognitive impairment in the aftermath of SARS-CoV-2 infection: a role for cerebrovascular Wnt/beta-Catenin and Caveolin-1 |
Sarah E. Lutz, University of Illinois at Chicago, USA | |
14:40-15:00 | Curcumin and omega-3 fatty acids: nutraceuticals against Alzheimer's disease |
Luz Velasco, Universidad Veracruzana, Mexico | |
15:00-15:20 | Slot Available |
15:20-15:40 | NeoRhythm: A Neurocardiac Electrophysiology Based Explainable EEG and ECG System for Detection of Neonatal Seizures |
Roshan Amurthur, Harker University, USA | |
15:40-16:00 | How Children Learn To Understand Language Meanings |
Stephen Grossberg, Boston University, USA | |
Abstract submissions are open now. To schedule your talk in the program, please email to: [email protected] |